AstraZeneca Reports Phase 3 Data for Daratumumab in Hidradenitis suppurativa

AstraZeneca today announced Phase 3 results for daratumumab in patients with hidradenitis suppurativa. The study demonstrated that daratumumab significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of hidradenitis suppurativa and support the continued development of daratumumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.